Business
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therape...
About this update from Caprock Mining Corp
[{"type":"text","content":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR\n\n\n\n INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n PR Newswire\n \n\n\n\n\n\n NEW YORK\n \n\n ,\n \n\n Sept. 13, 2025\n \n\n /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc.  (\"Capricor\" or the \"Company\") (NASDAQ: CAPR).  Such investors are advised to contact\n \n Danielle Peyton\n \n at\n \n [email protected]\n \n or 646-581-9980, ext. 7980.\n \n\n\n\n\n\n\n\n\n The investigation concerns whether Capricor and certain of its officers and/or directors have engaged in securities\n \n fraud\n \n or other unlawful business practices.\n \n\n\n\n [Click here for information about joining the class action]\n \n\n\n\n On\n \n May 5, 2025\n \n , Capricor issued a press release announcing that after \"the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy\", the FDA had \"confirmed its intent to hold an advisory committee meeting\" in connection with the BLA.\n \n\n On this news, Capricor's stock price fell\n \n $3.00\n \n per share, or 29.13%, to close at\n \n $7.30\n \n per share on\n \n May 6\n \n , 2025.\n \n\n Then, on\n \n June 20, 2025\n \n the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug's efficacy and safety.\n \n\n On this news, Capricor's stock price fell\n \n $3.68\n \n per share, or 30.82%, to close at\n \n $8.26\n \n per share on\n \n June 20, 2025\n \n .\n \n\n Pomerantz LLP, with offices in\n \n New York\n \n ,\n \n Chicago\n \n ,\n \n Los Ange...